Cargando…
Clinical, laboratory data and outcomes of 17 Iranian citrullinemia type 1 patients: Identification of five novel ASS1 gene mutations
Citrullinemia type 1 is an autosomal recessive metabolic disease caused by ASS1 gene mutations encoding argininosuccinic acid synthetase enzyme which is within the pathway of arginine and nitric oxide biosynthesis. Disease confirmation was done by ASS1 gene mutation analysis using next‐generation se...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995839/ https://www.ncbi.nlm.nih.gov/pubmed/35433176 http://dx.doi.org/10.1002/jmd2.12277 |
_version_ | 1784684369450893312 |
---|---|
author | Moarefian, Shirin Zamani, Mahdi Rahmanifar, Ali Behnam, Babak Zaman, Talieh |
author_facet | Moarefian, Shirin Zamani, Mahdi Rahmanifar, Ali Behnam, Babak Zaman, Talieh |
author_sort | Moarefian, Shirin |
collection | PubMed |
description | Citrullinemia type 1 is an autosomal recessive metabolic disease caused by ASS1 gene mutations encoding argininosuccinic acid synthetase enzyme which is within the pathway of arginine and nitric oxide biosynthesis. Disease confirmation was done by ASS1 gene mutation analysis using next‐generation sequencing, DNA Sanger sequencing. The study group was 17 citrullinemia type 1 patients from 10 unrelated families referred to Iranian National Society for Study on Inborn Errors of Metabolism's clinic between 2008 and 2020. Clinical, laboratory, and molecular data were retrospectively evaluated. Eleven different ASS1 gene mutations were detected in 13 (76%) of 17 neonatal, three (18%) of 17 late infantile, and one (6%) of 17 asymptomatic patients. Severe developmental delay and intractable seizures despite metabolic control was outcome of neonatal form survivor. Two late infantile form patients live metabolically controlled with quite normal performance. DNA mutations are as follows: seven missense, one nonsense, and two insertion/deletion mutations in 12, two, and three patients, respectively. Five novel mutations were detected including a homozygous GG deletion in exon 12 (c.790_791delGG;p.Gly264Profs*3) and a homozygous mutation in exon 7 (c.440C>T; p.Met147Thr), both causing infantile (late onset) form; a homozygous mutation in exon 6 (c.1130T>C; p.Met376Thr) causing neonatal form; two compound heterozygote mutations in exon 14 (c.1167_1168insC:p.Gly390Argfs*22& c.1186T>A; p.Ser396Thr) causing asymptomatic form. Five (38%) patients with classic neonatal form had mutation in exon 14 of ASS1 (c.1168G>A; p.Gly390Arg). Classic neonatal was the most common form of disease in Iranian‐studied patients and homozygote c.1168G>A was the most frequent ASS1 gene mutation. Global neonatal screening for citrullinemia type 1 in Iran is recommended and certain mutations can be used for screening severe form in this population. |
format | Online Article Text |
id | pubmed-8995839 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89958392022-04-15 Clinical, laboratory data and outcomes of 17 Iranian citrullinemia type 1 patients: Identification of five novel ASS1 gene mutations Moarefian, Shirin Zamani, Mahdi Rahmanifar, Ali Behnam, Babak Zaman, Talieh JIMD Rep Research Reports Citrullinemia type 1 is an autosomal recessive metabolic disease caused by ASS1 gene mutations encoding argininosuccinic acid synthetase enzyme which is within the pathway of arginine and nitric oxide biosynthesis. Disease confirmation was done by ASS1 gene mutation analysis using next‐generation sequencing, DNA Sanger sequencing. The study group was 17 citrullinemia type 1 patients from 10 unrelated families referred to Iranian National Society for Study on Inborn Errors of Metabolism's clinic between 2008 and 2020. Clinical, laboratory, and molecular data were retrospectively evaluated. Eleven different ASS1 gene mutations were detected in 13 (76%) of 17 neonatal, three (18%) of 17 late infantile, and one (6%) of 17 asymptomatic patients. Severe developmental delay and intractable seizures despite metabolic control was outcome of neonatal form survivor. Two late infantile form patients live metabolically controlled with quite normal performance. DNA mutations are as follows: seven missense, one nonsense, and two insertion/deletion mutations in 12, two, and three patients, respectively. Five novel mutations were detected including a homozygous GG deletion in exon 12 (c.790_791delGG;p.Gly264Profs*3) and a homozygous mutation in exon 7 (c.440C>T; p.Met147Thr), both causing infantile (late onset) form; a homozygous mutation in exon 6 (c.1130T>C; p.Met376Thr) causing neonatal form; two compound heterozygote mutations in exon 14 (c.1167_1168insC:p.Gly390Argfs*22& c.1186T>A; p.Ser396Thr) causing asymptomatic form. Five (38%) patients with classic neonatal form had mutation in exon 14 of ASS1 (c.1168G>A; p.Gly390Arg). Classic neonatal was the most common form of disease in Iranian‐studied patients and homozygote c.1168G>A was the most frequent ASS1 gene mutation. Global neonatal screening for citrullinemia type 1 in Iran is recommended and certain mutations can be used for screening severe form in this population. John Wiley & Sons, Inc. 2022-03-09 /pmc/articles/PMC8995839/ /pubmed/35433176 http://dx.doi.org/10.1002/jmd2.12277 Text en © 2022 The Authors. JIMD Reports published by John Wiley & Sons Ltd on behalf of SSIEM. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Reports Moarefian, Shirin Zamani, Mahdi Rahmanifar, Ali Behnam, Babak Zaman, Talieh Clinical, laboratory data and outcomes of 17 Iranian citrullinemia type 1 patients: Identification of five novel ASS1 gene mutations |
title | Clinical, laboratory data and outcomes of 17 Iranian citrullinemia type 1 patients: Identification of five novel
ASS1
gene mutations |
title_full | Clinical, laboratory data and outcomes of 17 Iranian citrullinemia type 1 patients: Identification of five novel
ASS1
gene mutations |
title_fullStr | Clinical, laboratory data and outcomes of 17 Iranian citrullinemia type 1 patients: Identification of five novel
ASS1
gene mutations |
title_full_unstemmed | Clinical, laboratory data and outcomes of 17 Iranian citrullinemia type 1 patients: Identification of five novel
ASS1
gene mutations |
title_short | Clinical, laboratory data and outcomes of 17 Iranian citrullinemia type 1 patients: Identification of five novel
ASS1
gene mutations |
title_sort | clinical, laboratory data and outcomes of 17 iranian citrullinemia type 1 patients: identification of five novel
ass1
gene mutations |
topic | Research Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995839/ https://www.ncbi.nlm.nih.gov/pubmed/35433176 http://dx.doi.org/10.1002/jmd2.12277 |
work_keys_str_mv | AT moarefianshirin clinicallaboratorydataandoutcomesof17iraniancitrullinemiatype1patientsidentificationoffivenovelass1genemutations AT zamanimahdi clinicallaboratorydataandoutcomesof17iraniancitrullinemiatype1patientsidentificationoffivenovelass1genemutations AT rahmanifarali clinicallaboratorydataandoutcomesof17iraniancitrullinemiatype1patientsidentificationoffivenovelass1genemutations AT behnambabak clinicallaboratorydataandoutcomesof17iraniancitrullinemiatype1patientsidentificationoffivenovelass1genemutations AT zamantalieh clinicallaboratorydataandoutcomesof17iraniancitrullinemiatype1patientsidentificationoffivenovelass1genemutations |